Pricing Log in Create free account
Friday 6 November 2026 Export AEMD’s income statement to Excel — free account

Aethlon Medical, Inc.

AEMD Healthcare Medical Devices

Aethlon Medical, Inc.’s revenue for fiscal 2023 (year ended March 2023) was $574,200.00, up 95.2% from fiscal 2022.

EPS
+90.5%
Free cash flow
−11.1%

Quarter to June 2026, against a year earlier

5.47 0.16 +3.01%
Market cap
$8.5M
P/E
0.0×
Fwd P/E
−0.3×
Dividend yield
—
F-score
5/9
Altman Z
−10.75
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 8.51
Revenue ttm 0.74
Net income ttm (6.94)
Free cash flow ttm (7.20)
Net debt Q (4.93)
Valuation
P/E 0.00
Forward P/E (0.34) (negative: loss-making)
Price / sales 2.86
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.40
Financial health
Current ratio Q 5.42 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (22.54)
Growth
Revenue growth Q +335.00% (above 0%: growing)
Operating income growth Q +11.89% (above 0%: growing)
EPS, this year +87.76% (at or above 15%: strong)
EPS, next year A +70.59% (at or above 15%: strong)
Revenue, next year A −7.12% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +76.48% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −2.7×, against a ten-year median of 9.2×; over the ten years it ranged from −44.2× in 2022 to 86.6× in 2018.
P/S against its own 10 years 9.97%
10-year low 10-year high
P/B against its own 10 years 14.46%
10-year low 10-year high
EV/FCF against its own 10 years 31.43%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 5 6 5 5
Receivables — — — —
Inventory — — — —
Other — — — —
6 6 6 6
2024 2025 2026 Q'26
Payables 1 1 0 0
ST’ Debt — — — —
Other 1 1 1 0
2 2 1 1

Compound Annual Growth %

10y 5y 3y
Sales (7.33%) 30.87% (4.06%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 12.52% (12.07%) (31.29%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY27 Estimate −4.05 Actual −4.02

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q1 FY26 −34.00 −42.50 Miss by 8.50
Q2 FY26 −8.50 −18.70 Miss by 10.20
Q3 FY26 −10.05 −12.25 Miss by 2.20
Q1 FY27 −4.05 −4.02 Beat by 0.03
Q2 FY27 −2.91 — Reports 11 November 2026

EPS $

Jun Sep Dec Mar Year
’26 (4.02) — — — —
’26 (42.50) (18.70) (12.25) (7.43) (53.05)
’25 (136.00) (80.00) (50.25) (171.37) (429.00)
’24 (520.00) (488.00) (548.00) (364.00) (1.94k)
’23 (760.00) (720.00) (480.00) (440.00) (2.36k)
’22 (640.00) (520.00) (640.00) (1.00k) (2.84k)
’21 (600.00) (600.00) (800.00) (600.00) (2.60k)
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 — — — — —
’23 — — — — 1
’22 0 0 0 0 0
’21 — — 1 0 1
’20 0 — 0 0 1
’19 0 — — 0 0
’18 — — 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (2) — — — —
’26 (2) (2) (2) (2) (7)
’25 (2) (2) (2) (2) (8)
’24 (2) (3) (2) (3) (10)
’23 (3) (3) (2) (3) (11)
’22 (2) (2) (3) (3) (10)
’21 (1) (1) (2) (2) (7)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (2) — — — —
’26 (2) (2) (2) (2) (7)
’25 (2) (2) (2) (2) (8)
’24 (3) (3) (2) (3) (10)
’23 (3) (4) (2) (3) (11)
’22 (2) (2) (3) (3) (10)
’21 (1) (1) (2) (2) (7)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jun ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 0 0 0 1 1 0 1 — — — 1 +6.6% — — — —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — — — 0.00 0.0 pt
EBT (7) (6) (6) (6) (8) (10) (12) (12) (13) (7) (7) (0.2%)
EBT margin, % (1,863.48) (3,810.03) (2,708.84) (981.24) (1,197.31) (3,542.11) (2,095.05) 0.00 0.00 0.00 0.00 +1,863.5 pt
Net income (7) (6) (6) (6) (8) (10) (12) (12) (13) (7) (7) (0.2%)
Per share, $
Per share, $ Revenue 3,030.14 748.00 765.33 722.44 219.70 79.51 112.59 0.00 0.00 0.00 0.00 n/m
Earnings (56,371.82) (27,586.21) (20,389.81) (7,480.00) (2,600.00) (2,840.00) (2,360.00) (1,944.00) (429.00) (53.05) (42.40) (53.9%)
Cash flow (27,093.51) (19,553.50) (14,311.33) (5,775.11) (2,254.97) (2,639.78) (2,059.82) (1,607.90) (245.05) (51.92) (18.66) (50.1%)
Capex (126.74) (124.00) 0.00 (168.56) (19.97) (94.38) (184.92) (39.83) 0.00 (0.03) (0.04) (60.8%)
Free cash flow (27,220.25) (19,677.50) (14,311.33) (5,943.67) (2,274.93) (2,734.16) (2,244.75) (1,647.73) (245.05) (51.94) (18.70) (50.1%)
Book value 4,601.24 30,164.00 7,663.67 10,308.22 3,097.90 4,592.27 2,953.76 915.29 164.21 36.25 13.52 (41.6%)
Shares, m 0 0 0 0 0 0 0 0 0 0 0 +116.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — — — 0.00 0.0
P/S 32.88 31.28 42.25 7.49 19.04 73.45 10.60 — — — 2.86 31.0
P/B 32.95 2.78 6.97 0.59 2.62 1.27 0.52 — — — 0.40 6.8
EV/Sales 31.14 19.86 34.45 (4.47) 12.01 18.38 (7.96) — — — (2.66) 14.8
EV/FCF (5.27) (2.71) (3.03) 0.61 (2.25) (0.53) 0.51 — — — 0.27 (1.8)
Cash, $m
Cash, $m Operating cash flow (4) (4) (4) (5) (7) (10) (11) (10) (8) (7) (7) +8.0%
Capex 0 0 — 0 0 0 (1) 0 — 0 0 (15.2%)
Free cash flow (4) (4) (4) (5) (7) (10) (11) (10) (8) (7) (7) +7.9%
Balance, $m
Balance, $m Working capital 1 7 2 9 9 16 14 4 4 4 5 +17.2%
Net debt (1) (6) (4) (10) (10) (17) (15) (5) (6) (5) (5) +19.1%
Shareholders’ equity 1 6 2 9 9 17 15 6 5 5 5 +26.3%
Returns, %
Returns, % ROA (341.96) (125.12) (107.97) (87.85) (74.91) (69.24) (65.15) (94.80) (171.58) (104.46) (120.22) +237.5 pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (1,399.70) (2,435.36) 0.00 0.00 (1,665.51) 0.0 pt
ROE (693.69) (171.38) (148.70) (110.12) (84.94) (79.25) (75.06) (117.21) (245.88) (142.89) (160.91) +550.8 pt
People
People Employees 7 6 6 8 10 14 15 14 9 9 — +2.8%
Revenue/emp, $m 0.06 0.02 0.04 0.08 0.07 0.02 0.04 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2023 · latest quarter Mar 2022 · fundamentals updated 26 Oct 2026

Aethlon Medical, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PAVM PAVmed Inc. $12.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%) Compare
MODD Modular Medical, Inc. $12.2M — (loss-making) — — n/m −5.61% (below 0%: shrinking) 0.00% 0.00% Compare
IRIX IRIDEX Corporation $11.9M — (loss-making) — (loss-making) −7.41% (below 0%: shrinking) n/m +130.24% (above 0%: growing) 34.19% (8.19%) Compare
SINT SINTX TECHNOLOGIES, INC. $11.5M — (loss-making) — (loss-making) +952.88% (above 0%: growing) n/m +47.37% (above 0%: growing) 62.19% (74.66%) Compare
BTCY Biotricity Inc. $10.9M — (loss-making) — (loss-making) +10.40% (above 0%: growing) n/m +235.83% (above 0%: growing) 82.55% 3.70% Compare
AEMD Aethlon Medical, Inc. $8.5M — (loss-making) — (loss-making) +335.00% (above 0%: growing) n/m −11.13% (below 0%: shrinking) 0.00% 0.00%
NMTC NeuroOne Medical Technologies Corporation $7.8M — (loss-making) — (loss-making) +16.33% (above 0%: growing) n/m +26.91% (above 0%: growing) 59.94% (122.87%) Compare
BMRA Biomerica, Inc. $7.4M — (loss-making) 11.4× −8.33% (below 0%: shrinking) n/m −199.25% (below 0%: shrinking) 8.14% (97.00%) Compare
INBS Intelligent Bio Solutions Inc. $5.8M — (loss-making) — (loss-making) +51.10% (above 0%: growing) n/m −31.59% (below 0%: shrinking) 43.23% (360.19%) Compare
Median of peers $11.2M — — +16.33% — +10.65% 38.71% (85.83%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 1 September 2026

Ownership

Directors and executive officers, together 0.60%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Aethlon Medical, Inc. (AEMD) Latest News

17 Sep

Impact 5 · · InvestorsHub
Impact 4 · · biopharmadive.com
Impact 4 ·

19 Aug

Impact 3 ·

14 Aug

Impact 3 · · Moby transcript

13 Aug

Impact 3 ·

13 Jul

Impact 3 ·

6 Jul

Impact 3 ·

26 Jun

Impact 3 ·

17 Jun

Impact 3 ·

16 Jun

Impact 3 · transcript

11 Jun

Impact 3 ·
Impact 3 · · Moby transcript

10 Jun

Impact 3 · · The Motley Fool transcript
Impact 3 · · PR Newswire

24 Mar

Impact 4 · · Zacks Small Cap Research
Impact 4 ·

18 Mar

Impact 3 · · Zacks Small Cap Research

12 Mar

Impact 4 · · PR Newswire

18 Feb

Impact 4 · · Zacks Small Cap Research

15 Feb

Impact 4 · · GuruFocus.com

13 Feb

Impact 3 · · Moby transcript

12 Feb

Impact 3 · · PR Newswire

5 Dec

Impact 3 · · PR Newswire

2 Dec

Impact 4 · · PR NewswireMT NewswiresMotley FoolMT NewswiresGuruFocus.comMotley Fool

14 Nov

Impact 4 · · Zacks Small Cap Research

12 Nov

Impact 3 · · PR Newswire

21 Oct

Impact 4 · · Zacks Small Cap Research

10 Oct

Impact 4 · · Zacks Small Cap Research

7 Oct

Impact 4 · · PR Newswire
stockrow.com/AEMD · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com